Congressionally Directed Medical Research Programs -- Duchenne Muscular Dystrophy Research Program -- Translational Research Award

Funding Agency:
Department of Defense

The FY21 DMDRP Translational Research Award mechanism supports translational research that will accelerate the movement of promising ideas in DMD research into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science.

This mechanism is intended to support established projects that have moved beyond the realm of basic research and have the potential to result in a near-term impact in clinical research or the clinic. Research projects investigating therapies that will be efficacious across the life span, particularly in adolescents and adults are strongly encouraged. Pilot, proof-of-principle clinical trials and correlative studies to better inform development of drugs, devices, and other interventions are allowed.

All applications must include preliminary data relevant to DMD and the proposed project. The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public.

Deadlines:

  • Required Pre-Application Submission Deadline:   August 11, 2021
  • Application Submission Deadline: December 1, 2021

Agency Website

Areas of Interest

All applications for the FY21 DMDRP Translational Research Award must address at least one of the following Focus Areas:

• Translational and clinical studies, novel interventions, and drug and biologic delivery technologies designed to improve care and quality of life in areas such as: o Cognitive function o Cardiac o Endocrinology (including bone health and growth) o Skeletal muscle

• Assessment of clinical trial tools and outcome measures such as: o Discovery and qualification of pharmacodynamic, prognostic, and predictive biomarkers, including potential surrogate markers o Novel clinical outcome assessment o Patient-centered outcomes (e.g., quality of life, activities of daily living) o Secondary data analysis that helps to address clinical research tool validation and/or to understand natural history

• Extension or expansion of existing preclinical translational data in support of a specific therapeutic development path (such as optimizing delivery to target tissues, including drug exposure, independent replication, and comparative studies)

Eligibility Requirements

Independent investigators at all academic levels may be named as PI on the application.

An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.

Amount

$1,300,000

Amount Description

The anticipated direct costs budgeted for the entire period of performance for an FY21 DMDRP Award will not exceed $1.3M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Funding Type

Grant

Eligibility

Faculty
Junior Faculty
Medical Fellow/Resident
Post Doctoral Fellows

Category

Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

August 11, 2021